<DOC>
	<DOCNO>NCT01706783</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , availability distribution body once-weekly long-acting growth hormone ( NNC0195-0092 ) compare daily Norditropin NordiFlex® adult growth hormone deficiency ( GHD ) .</brief_summary>
	<brief_title>A Trial Investigating Safety , Tolerability , Availability Distribution Body Once-weekly Long-acting Growth Hormone Compared Once Daily Norditropin NordiFlex® Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adults GHD define consensus guideline diagnosis treatment adult GHD Stable human growth hormone ( hGH ) replacement therapy least 3 month Participation another clinical trial within 3 month receipt investigational medicinal product within 3 month prior randomisation Active malignant disease malignant disease within last 5 year exception fully treat local basal cell carcinoma carcinoma situ cervix Proliferative retinopathy judge retinaphoto within last year concomitant diabetes Heart insufficiency , New York Heart Association ( NYHA ) class 2 Adults GHD poorly control diabetes mellitus glycosylated haemoglobin ( HbA1c ) 64 mmol/mol ( 8.0 % ) and/or insulin treatment Stable pituitary replacement therapy le 3 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>